Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

Andus T, Geiger T, Hirano T, Northoff H, Ganter U, Bauer J, Kishimoto T, Heinrich PC (1987) Recombinant human B cell stimulatory factor 2 (BSF-2/IFN?2) regulates ?-fibrinogen and albumin mRNA levels in Fao-9 cell. FEBS Lett 221:18

Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku R, Akiyama Y (1990) In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelet. Blood 75: 1602

Bakker NPM, Van Erick MG, Botman CAD, Jonker M, Thart BA (1991) Collagen-induced arthritis in an outbred group of rhesus monkeys comprising responder and nonresponder animals. Relationship between the course of arthritis and collagen-specific immunity. Arthritis Rheum 34:616

Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M (1996) Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra arthritis study group. Arthritis Rheum 39:1092

Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC (1988) Recombinant human interleukin-6 (IL-6BSF-2/HFS) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347

Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C (1986) Experimental arthritis in a nonhuman primate. Lab Invest 54: 26

Ceuppens JL, Baroja ML, Lorre K, Van Damme J, Billiau A (1988) Human T cell activation with phytohemmagglutinin: the function of IL-6 as an accessory signal. J Immunol 141:3868

Courtenay JS Dallman MJ Dayan AD, Martin A, Mosedale B (1980) Immunization against heterologous type II collagen induced arthritis in mice. Nature 283: 666

Elliott MJ, Maini RN, Feldmann M, Kalden J, Antoni C, Smolen J, Leeb B, Breedveld F, Macfarlane J, Biji H, Woody J (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor ? (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105

Evans J, Yocum E, Maricic M, Gluck O, Tesser J, Chen Z, Baylink J, Fletcher M (1997) Results of an open label, dose-ranging, safety and pharmacokinetic trial of the humanized tumor necrosis factor antibody (HTA), bay 103356, in patients with active rheumatoid arthritis (RA). Arthritis Rheum 40: S224

Feldmann M, Elliott MJ, Woody JN, Maini RN (1997) Anti-tumor necrosis factor-? therapy of rheumatoid arthritis. Adv Immunol 64:283

Garman RD, Jacobs KA, Clark SC, Raulet DH (1987) B cell-stimulatory factor 2 (?2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci USA 84:7629

Gauldie J, Richards C, Harnish D, Landsdorp P, Baumann H (1987) Interferon (32B cell-stimulatory factor type 2 shares identity with monocyte-derived hepatocytesimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251

Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, Emery P (1991) Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol 86:145

Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB (1989) Interleukin 6 is expressed in high levels in psoriasis skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 86:6367

Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149

Hill RJ, Warren MK, Levin J (1990) Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J Clin Invest 85:1242

Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun K, Kishimoto T (1985) Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490

Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Kayama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B cell lymphocytes to produce immunoglobulin. Nature 324: 73

Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maim R, Feldman M, Kishimoto T (1988) Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18: 1797

Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, Yoshizaki K, Hirano T, Kishimoto T (1989) Involvement of interleukin-6 in mesangial proliferation of glomerulonephritis. J Immunol 143:3949

Houssiau FA, Devogelaer JP, Van Damme J, De Deuxchaisies CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum 31:784

Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M (1987) Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84:9035

Ishibashi T, Kimura H, Shikawa H, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1987) Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86:5953

Ishibashi T, Kimura H, Shikawa Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241

Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, Pawlowski T, Suematsu S, Kishimoto T (1991) Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. New Biologist 3:63?70

Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83

Klein B, Zhang XG, Jourdan MJC, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517

Koike K, Nakahata T, Takagi M, Kobayashi T, Ishiguro A, Tsujii K, Naganuma K, Okano A, Akiyama Y, Akabane T (1988) Synergism of BSF2/interleukin-6 and interleukin-3 on development of multipotential hemopoietic progenitors in serum free culture. J Exp Med 168: 879

Koike K, Nakahata T, Kubo T, Kikuchi T, Takagi M, Ishiguro A, Tsuji K, Naganuma K, Okano A, Akiyama Y, Akabane T (1990) Interleukin-6 enhances murine megakariocytopoiesis in serum-free culture. Blood 75: 2286

Le J, Fredrickson G, Reis L, Diamantsein T, Hirano T, Kishimoto T, Vilcek J (1988) Interleukin-2-dependent and interleukin-2-independent pathways of regulation of thymocyte function by interleukin-6. Proc Natl Acad Sci USA 85: 8643

Leary A, Ikebuchi K, Hirai Y, Wong G, Yang Y-C, Clark S, Ogawa M (1988) Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1a. Blood 71:1759

Lotz M, Jirik F, Kabouridis R, Tsoukas C, Hirano T, Kishimoto T, Carson D (1988) BSF-2/IL-6 is costimulant for human thymocytes and T lymphocytes. J Exp Med 167: 1253

Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52: 232

Maini R, Paulus H, Breedveld F, Charles P, Davies D, Grint P, Wherry J, Feldman M (1997) rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 40: S224

Mihara M, Kotoh M, Oda Y, Kumagai E, Takagi N, Tsunemi K, Takeda Y (1997) Anti-IL-6 receptor antibody suppress the onset of collagen arthritis in monkeys. Arthritis Rheum 40: S133

Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260:1808

Nijsten MWN, Degroot ER, TenDuis HJ, Klasen J, Hack CE, Aarden LA (1987) Serum levels of interleukin-6 and acute phase responses. Lancet II: 921

Nishimoto N, Yoshizaki K, Tagoh H, Monden M, Kishimoto S, Hirano T, Kishimoto T (1989) Elevation of serum interleukin-6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 50: 399

Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T (1987) Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 15: 249

Nordan RP, Pumphrey JG, Rudikoff S (1987) Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the routine macrophage cell line P388D1. J Immunol 139: 813

Nuki G, Rozman B, Pavelka K, Emery P, Lookabaugh J, Musikic P (1997) Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum 40: S224

Numata Y, Matsuura Y, Onishi S, Yamamoto Y, Ohno F, Tagoh H, Yoshizaki K, Fujimoto S, Yamamoto H (1991) Case report: interleukin-6 positive follicular hyperplasia in the lymph node of a patient with rheumatoid arthritis. Am J Hematol 36: 282

Ogawa M (1993) Differentiation and proliferation of hematopoietic stem cells. Blood 81: 2844

Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H, Monoden M, Gotoh M, Kishimoto T, Mori T (1992) Interleukin-6 as a new indicator for the inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein following surgical operation. Surgery 111: 201

Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T (1988) BSF-2/IL-6 functions as killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 141: 1543

Rubin AS, Healy CT, Martin LN, Baskin GB, Roberts ED (1987) Experimental arthropathy induced in rhesus monkeys (Macaca mulatta) by intradermal immunization with native bovine type II collagen. Lab Invest 57: 524

Sack U, Kinne R, Marx T, Heppt P, Bender S, Emmrich F (1993) Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 13: 45

Sander O, Rau R (1997) Long term observation of 80 patients treated with TNF? receptor-fusion protein (TNFR55-GG1, RO 45-2081). Arthritis Rheum 40:S224

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851

Smith HS, Steinberg AD (1983) Autoimmunity ? a perspective. Annu Rev Immunol 1: 175

Stanley ER, Bartocci A, Patinkin D, Rosendaal M, Bradley TR (1986) Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell 45:667

Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86: 7547

Sugita T, Furukawa O, Ueno M, Murakami T, Takata I, Tosa T (1993) Enhanced expression of interleukin-6 in rat and murine arthritis models. Int J Immunopharmacol 15:469

Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH (1988) B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 140: 508

Takai Y, Seki N, Senoh H, Yokota T, Lee F, Hamaoka T, Fujiwara T (1989) Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 32:594

Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90: 11924

Terato K, Arai H, Shimozuru Y, Fukuda T, Tanaka H, Watanabe H, Nagai Y, Fujimoto K, Okubo F, Cho F, Honjo S, Cremer MA (1989) Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum 32: 748

Tomita T, Takeuchi E, Tomita N, Morishita R, Hashimoto H, Kaneko M, Yamamoto K, Kameda Y, Ochi T (1997) In vivo transfection of NF-?B decoy reduced severity of rat collagen-induced arthritis as a gene therapy. Arthritis Rheum 40: S220

Trentham DE (1982) Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum 25: 911

Trentham DE, Townes AS, Kang AH (1977) Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146: 857

Van Damme J, Opdenakker G, Simpson RJ, Rubia MR, Cayphas S, Vink A, Billiau A, Van Snick JV (1987) Identification of the human 26-kDa protein, interferon ?2 (IFNb2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 165:914

Van Den Berg WB, Joosten LAB, Helsen M, Van De Loo FAJ (1994) Amelioration of established routine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95: 237

Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259

Williams RO, Feldman M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784

Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602

Yamazaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN?2) receptor. Science 241: 825

Yoo TJ, Kim S-Y, Stuart JM, Floyd RA, Olson GA, Cremer MA, Kang AH (1988) Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med 168:777

Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T (1982) Induction of proliferation and Igs-production in human B leukemic cells by anti-immunglobulins and T cell factors. J Immunol 128:1296

Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T (1989) Pathogenic significance of interleukin-6(IL-6BSF-2) in Castleman's disease. Blood 74: 1360

Yoshizaki K, Nishimoto N, Matsumoto K, Tagoh H, Taga T, Deguchi Y, Kuritani T, Hirano T, Kishimoto T (1990) Interleukin-6 and its receptor expression on the epidermal keratinocytes. Cytokine 2: 281